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Combined Modality Therapies for
High-Risk Prostate Cancer: Narrative
Review of Current Understanding
and New Directions
Benjamin A. Greenberger*, Victor E. Chen and Robert B. Den
Department of Radiation Oncology, Sidney Kimmel Medical College and Cancer Center, Thomas Jefferson University,
Philadelphia, PA, United States
Despite the many prospective randomized trials that have been available in the past
decade regarding the optimization of radiation, hormonal, and surgical therapies for
high-risk prostate cancer (PCa), many questions remain. There is currently a lack of
level I evidence regarding the relative efficacy of radical prostatectomy (RP) followed
by adjuvant radiation compared to radiation therapy (RT) combined with androgen
deprivation therapy (ADT) for high-risk PCa. Current retrospective series have also
described an improvement in biochemical outcomes and PCa-specific mortality through
the use of augmented radiation strategies incorporating brachytherapy. The relative
efficacy of modern augmented RT compared to RP is still incompletely understood.
We present a narrative review regarding recent advances in understanding regarding
comparisons of overall and PCa-specific mortality measures among patients with
high-risk PCa treated with either an RP/adjuvant RT or an RT/ADT approach. We give
special consideration to recent trends toward the assembly of multi-institutional series
targeted at providing high-quality data to minimize the effects of residual confounding.
We also provide a narrative review of recent studies examining brachytherapy boost and
systemic therapies, as well as an overview of currently planned and ongoing studies that
will further elucidate strategies for treatment optimization over the next decade.
Keywords: prostate neoplasms, high-risk, clinically localized, prostatectomy, radiotherapy
INTRODUCTION
Of the cases of newly diagnosed localized prostate cancer (PCa),∼15% are discovered as high-risk
disease (1). There has been clinical equipoise surrounding the issue of selecting optimal definitive
therapy, as treatment paradigms have evolved to incorporate both upfront surgery and radiation
approaches (2). Definitive therapy for newly diagnosed cases of high-risk disease now routinely
includes radical prostatectomy (RP) followed by a consideration of adjuvant radiation (ART) and
androgen deprivation therapy (ADT) or a combination of external beam radiation therapy (XRT)
with androgen deprivation therapy (ADT) with or without the addition of brachytherapy (BT).
While treatment of favorable-risk localized disease has benefited from the relatively recent
publication of randomized controlled data demonstrating no detectable difference in PCa-specific
mortality (PCM) between RP- and RT-based approaches (3), there has not been a large-scale
randomized clinical trial representing patients with high-risk disease. The available trials in the
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setting of high-risk PCa that compare outcomes between RP and
RT cohorts are limited by small numbers of high-risk patients
(4, 5). Comparing RT and RP over the past several decades has
been somewhat of a moving target, as paradigms for treatment
of high-risk disease have shifted with steady innovation. Recent
practice-shaping trends in RT clinical trials and retrospective
investigation have explored optimization of combined modality
therapies utilizing radiation, including XRT + BT boost (6),
demonstration of efficacy and duration optimization of ADT
with and without dose-escalated RT (7–15), incorporation of
whole-pelvis XRT for high-risk patients (16–18), assessment of
safety of hypofractionation in the setting of high-risk disease
(19–22), and exploration of addition of systemic therapies (23–
26). Despite the rapid advancement of understanding regarding
the optimization of modern therapies, the decision regarding
primary intervention with RP vs. RT has remained most elusive.
As such, we have sought to provide a narrative review focusing
on advancements in the understanding of treatment efficacy of
optimized RT- and RP-based approaches to clinically localized
high-risk PCa. We have also sought to provide a brief overview
of upcoming clinical trials anticipated over the next decade.
METHODS
We aimed to review the available literature regarding the
relative efficacy of modern strategies incorporating RP or
RT-first techniques targeted at the definitive treatment of
high-risk PCa. We constructed search terms corresponding
to three separate reference databases: PubMed, Scopus, and
Cochrane Central Register of Controlled Trials. Subject
headings and MeSH terms were incorporated with text/keyword
terms for “radical prostatectomy,” “radiotherapy,” “outcome,”
“survival,” “mortality, “systemic therapy,” and related terms.
These were assembled into search strings tailored for each
database (Supplementary Table 1). Given the heterogeneity
in classification schemes of PCa (2), we did not discriminate
with regard to the definition of high-risk and aimed to target
the common definitions (Supplementary Table 2), as well as
cohorts constructed to examine subsets of common definitions
of high-risk disease, such as Gleason 9–10. Cohorts including,
though not exclusively focusing on, locally advanced patients
with nodal disease were included, as many investigators did
not know nodal status preoperatively. Additional details of the
literature search are described in Supplementary Table 1. Given
changes in practice patterns concerning RT dose-escalation
and ADT use in high-risk disease, we drew principally from
studies published within the past decade (since 2009). Reference
lists of reviews published on clinically localized PCa were
also checked for additional relevant publications (26–32). Our
primary outcomes of interest were PCM and overall mortality
(OM), although a meta-analysis focusing on these outcomes was
not the purpose of this review. We excluded studies focusing
primarily on surrogate measures of progression or PCM, such
as biochemical recurrence/failure (BCR/BF). Studies focusing
on toxicity, patient-reported outcomes, and quality of life are
beyond the scope of this review.
The United States national online registry of clinical trials
located at clinicaltrials.gov, as managed by the National
Library of Medicine at the National Institutes of Health,
was queried for all current active trials with keyword terms
“prostate cancer,” “prostate cancer Stage III,” and related
synonymous terms (Supplementary Table 3). The search was
limited to exclude trials that had been suspended, terminated,
completed, withdrawn, or trials with unknown status. Each
clinical trial in the resulting list was individually reviewed
for relevance and inclusion in the table of current trials of
interest. Furthermore, multiple large, geographically disparate
U.S. academic institutions with searchable lists of active clinical
trials including University of California San Diego, University
of California San Francisco, Thomas Jefferson University,
MD Anderson, and Memorial Sloan Kettering Cancer Center
were queried for trials investigating PCa therapies to ensure
completeness of the initial clinicaltrials.gov search. Ongoing trials
that had been previously quoted or otherwise referenced in
the other sources surveyed in this review paper were included
in Table 5.
Lack of Data From Randomized
Clinical Trials
Randomized controlled trials (RCTs) providing insight into
relative efficacy of upfront RP or RT modalities have remained
limited for the past several decades, which has prompted the
use of alternative comparison methods to address investigation
(Supplementary Table 4). There were two early RCTs in PCa,
including one performed by the Uro-Oncology research group
before routine use of prostate-specific antigen (PSA) and one
by the Japanese Study Group for Locally Advanced Prostate
Cancer (5, 33). Only the latter provided representation of high-
risk disease. Multiple additional studies were initiated and failed
to accrue enough patients to investigate mortality endpoints (34–
37). These early studies, when reported, demonstrated possibly
improved survival outcomes in favor of surgery across localized
disease risk groups. However, there were significant concerns
regarding stage migration, small sample size, short follow-
up, and other methodological limitations of these trials that
limited their impact (38). A more recent study of patients with
localized or locally advanced PCa undergoing RP or XRT +
BT with ADT did not demonstrate a statistically significant
difference in OM or PCM. The study was underpowered to assess
survival outcomes, though, with only 89 patients (4) (Table 1).
Although not providing information regarding high-risk disease,
the ProtecT study represents a more modern, well-designed,
randomized trial in PCa. The comparison of RT- and RP-based
modalities contained in this trial did not demonstrate statistically
significant differences in PCM (p = 0.48), with OM rates also
demonstrably comparable between the arms. Interpretation of
this trial concerning its RT vs. RP outcomes is limited due to
a lack of statistical power, as the observed PCM was lower than
anticipated (38, 44). In the setting of high-risk disease, a modern
clinical trial targeting a randomization between upfront RT- and
RP-based definitive treatment has recently been initiated with the
SPCG-15 trial. This trial compares standard (RT + ADT) and
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experimental (RP with extended pelvic lymph node dissection
and with addition of adjuvant/salvage RT and ADT) treatment
at 23 centers in Denmark, Finland, Norway, and Sweden (45)
(Table 5). As such an effort is just getting underway, it is likely
that for the next decade, conclusions regarding the relative
efficacy of RP- vs. RT-based approaches for high-risk disease will
not be drawn from randomized data.
Limited Ability to Investigate Mortality
Endpoints With Limited-Institution
Observational Data
Despite the lack of RCTs that provide data regarding high-
risk disease, multiple institutions have published retrospective
data comparing RP and RT outcomes. Selected studies are
presented in Table 1, with a more comprehensive list in
Supplementary Table 4. The largest of these are retrospective
studies published by Memorial Sloan Kettering, Mayo Clinic/Fox
Chase, and Cleveland Clinic (39–41). The Memorial Sloan
Kettering Study described outcomes for cT1c–T3b PCa who
underwent either RP with pelvic lymphadenectomy or RT
(without coverage of pelvic lymph nodes) to a dose of at least
81Gy. At a median follow-up time of 5 years, the study reported
a 7.8% difference in 8-year metastatic progression in the high-
risk subset favoring RP. The hazard ratio (HR) for PCM in
RP vs. RT is 0.32 [95% confidence interval (CI), 0.13–0.80;
P = 0.015] in favor of surgery after adjusting for preoperative
Kattan nomogram, age, and treatment year. Adjusted HRs for the
high-risk subset were not published. The treatment of high-risk
patients in this study was additionally limited by the lack of long-
term ADT and possibly the lack of pelvic lymph node irradiation,
as has been discussed (2). There is some continuing equipoise
regarding the latter issue. The relative benefit of pelvic lymph
node irradiation in intermediate- to high-risk PCa is currently
undergoing prospective evaluation in RTOG 0924, although the
majority of clinical trials publishing outcomes for combination
TABLE 1 | Selected representative institutional studies of comparative effectiveness of radiotherapy and radical prostatectomy in high-risk prostate cancer.
Study type Representative study Summary description Endpoints Findings related to PCM,
OM
Key limitations
Randomized controlled
trial
Lennernäs et al. (4)
(accrual 1996–2001)
89 patients, T1b–T3a,
N0, M0 and PSA
≤50 ng/ml. All
underwent total
androgen blockade (6
months). RP vs. XRT +
BT.
Self-reported
HRQoL.
Secondary
endpoints:
OM, PCM
10-year results
RP−13.3% PCM, 26.7%
OM
XRT + BT: 4.5% PCM,
20.5% OM
No statistically
significant differences
Limited sample size, lack of
statistical power
Single or limited
multi-institutional
observational study
Zelefsky et al. (39)
Memorial Sloan Kettering
(accrual 1993–2002)
2,380 pts (including
409 NCCN high-risk)
with T1c-T3b PCa were
treated with
intensity-modulated
XRT (≥81Gy) or RP
Primary endpoint:
distant metastasis.
Secondary
endpoint: PCM
5-year results with 95% CI
RP: 1.0% (0.1–7.0%) PCM
RT: 3.7% (1.8–7.4%) PCM
Hazard ratios not reported
for high-risk subset. 3–6
months ADT in 56% of
patients. No adjuvant ADT
in high-risk patients
Boorjian et al. (40)
Mayo Clinic, Fox Chase
(accrual 1988–2004)
1,847 NCCN high-risk
patients, treated with
RP or XRT with pelvic
nodes included
Systemic
progression, PCM,
OM
10-year PCM
8% (RP), 8% (XRT + ADT),
and 12% (XRT alone).
Worse HR (1.6) for OM for
XRT/ADT compared with
RP, though not significant
for PCM
56% ADT utilization in XRT
cohort, low radiation dose
of median 72Gy XRT
Ciezki et al. (41)
Cleveland Clinic
(accrual 1996–2012)
2,557 NCCN high-risk
patients, treated with
RP or XRT (≥78Gy) or
BT (LDR 144Gy)
PCM, BF, clinical
relapse
5-year results
PCM was 5.3% XRT, 3.2%
LDR, and 2.8% for RP
> 6-months duration of
ADT in only 26% of patients
with XRT
Tilki et al. (42)
Chicago Prostate Cancer
Center, USA and
Martini-Klinik Prostate
Cancer Center, Germany
(accrual 1992–2013)
639 patients with
Gleason 9–10 treated
with RP ± adjuvant RT
± ADT or XRT + BT +
ADT (median 6 months)
OM, PCM 5-year PCM: 21.89% (RP),
3.93% (RP + XRT), 9.83%
MaxRP, 27.04% RP + ADT
vs.
5-year PCM:
2.22% (MaxRT)
Surgery and RT comparison
cohorts at geographically
different centers
Reichard et al. (43)
MD Anderson (accrual
2004–2013); comparison
with Matched SEER Cohort
304 patients with
NCCN high-risk or
very-high-risk treated
with RP or XRT + ADT
BF, DM, OM, LF 5-year OM
RP = 4.3%
RT + ADT = 1.5%
HR NS
Limited patient number to
assess OM or PCM
endpoints; only 3.9% of RP
patients received adjuvant
RT, no PCM reported
BF, biochemical failure; BT, brachytherapy; DM, distant metastases; Gy, gray; HR, hazard ratio; HRQoL, health-related quality of life; LDR, low-dose-rate; MaxRP, RP followed by adjuvant
radiation within 1 year; MaxRT, XRT + brachytherapy ± ADT; OM, overall mortality; NS, not significant; PCM, prostate cancer-specific mortality; PSA, prostate-specific antigen; XRT,
external beam radiation therapy.
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XRT and ADT for high-risk PCa included pelvic lymph node
irradiation (7–9, 12).
Large cohorts focusing more on a high-risk group were
reported by Mayo Clinic/Fox Chase (40) and Cleveland Clinic
(41). The former group focused on RP vs. XRT, with the
latter additionally comparing patients who received low-dose-
rate (LDR) BT. The Mayo Clinic/Fox Chase group published
outcomes for 1,847 National Comprehensive Cancer Network
(NCCN) high-risk patients, treated with RP or XRT. Pelvic lymph
node coverage was included in the radiation portal. The study
principally reported a 10-year cancer-specific survival rate of 92,
92, and 88% after RP, XRT + ADT, and XRT alone, respectively
(P= 0.06). After adjusting for case mix, there were no significant
differences in systemic progression (HR, 0.78; 95% CI, 0.51–1.18;
P = 0.23) or PCM (HR, 1.14; 95% CI, 0.68–1.91; P = 0.61)
between patients who received XRT + ADT and patients who
underwent RP. The risk of OM, however, was greater after XRT
+ ADT than after RP (HR, 1.60; 95% CI, 1.25–2.05; P = 0.0002).
The study is strengthened by follow-up>10 years for the patients
receiving RP and 6 years for patients receiving RT, as well as a
median duration of ADT of 22.8 months. It is limited, though, by
the low radiation doses used (72Gy). The Cleveland Clinic cohort
published cancer-specific survival outcomes of 2,557 patients
with NCCN high-risk PCa treated with XRT ± ADT, LDR ±
ADT, or RP±XRT (41). The PCM at 5 and 10 years, respectively,
was 5.3 and 11.2% for XRT, 3.2 and 3.6% for LDR BT, and 2.8
and 6.8% for RP (P = 0.0004). Although radiation dose utilized
was notably higher than that of the Mayo/Fox Chase Study, with
patients receiving at least 78Gy, the utilization rate of long-
course ADT in high-risk patients was low. Only 26% of patients
receiving RT had an ADT duration >6 months. This low rate
limits the interpretation of the HR from the study in favor of RP
when comparing RP vs. XRT.
There have been more recently published single-institution
studies demonstrating improved compliance with dose-escalated
RT and long-course ADT, though the numbers of patients
included have been demonstrably lower (43, 46). A study by
Washington University reported outcomes for 62 propensity-
score-matched pairs of patients with NCCN high-risk PCa
receiving RP or XRT (46). Although not achieving uniform
compliance, the study states that 80.6% of the patients receiving
XRT received 2 years of total ADT. The median XRT dose
was 75.6Gy. Although PCM was not reported, 5-year rates
of metastasis for RP and RT were 33 and 8.9%, respectively
(P = 0.003), with no difference in overall survival detected. The
more recent study was published by MD Anderson, describing a
cohort of 304 patients with NCCN high or very high-risk PCa
treated from 2004 to 2013 with RP or XRT + ADT (43). The
XRT + ADT group included 73 patients, though 100% received
ADT with a median duration of 22 months, and all but one
patient received≥75.6Gy. At 83months median follow-up, there
was no difference in local recurrence (HR, 2.7; 95% CI, 1.0–7.9;
P = 0.06), distant metastasis failure (HR, 2.5; 95% CI, 0.8–7.8;
P = 0.1), or OM (HR, 1.35; 95 CI, 0.4–4.8; P = 0.6) between
patients undergoing RP vs. RT + ADT, with definition of HR
in this study favoring RT at higher values. Although both of
these studies demonstrate improved compliance with modern
XRT + ADT standard of care compared with previous single-
institutional studies, the patient sample size limits statistical
power to detect differences in PCM or OM.
Although large single or limited-institutional studies are
available comparing RP vs. RT outcomes, the shift that only
happened relatively recently to modern ADT and radiation dose
regimens continues to limit interpretation of the most extensive
studies. Newer single-institutional series will likely provide a
more relevant comparison of optimized RT/ADT vs. RP with less
confounding as data mature.
Population-Based Databases
With the proliferation of cancer registries, a multitude of PCa
outcome studies have been published utilizing large databases to
examine late-termOMor PCM (47). Studies using databases with
limited reporting of ADT and RT dose compliance include those
utilizing PCOS [Surveillance, Epidemiology, and End Results
(SEER)], PcBaSe, and other early organized databases. These
databases demonstrate a somewhat limited ability to account
for adequacy of combined modality therapy in the setting
of high-risk treatment due to difficulty accounting for dose-
escalation as well as 1.5 months or greater of ADT in the context
of XRT/ADT definitive management (Supplementary Table 5)
(48–51). National Cancer Database (NCDB) studies typically
allow for reporting of whether a patient received ADT during
or after therapy. The duration of treatment, however, is not
reported. NCDB studies are also limited by no report of PCM
(52–54). SEER-Medicare studies, on the other hand, have been
able to report the median number of days of ADT in some
instances, with assessment of both OM and PCM possible (55–
57). Virtually all databases have limited difficulty to provide
full details regarding the RT plan, including consideration
of dose and pelvic nodal treatment. Several representative
studies drawn from these databases are shown in Table 2 and
Supplementary Table 4. The vast majority of population-based
studies point to RT relying solely on external beam without BT as
associated with worse OM (49, 51, 52, 56, 57) and PCM (48–51,
55–57) than RP. Ability to eliminate residual confounding, most
notably to ensure both adequate RT dose and ADT duration, in
any of these studies is limited.
Early Array of Meta-Analyses
To cope with the difficulties presented by the lack of randomized
data in the setting of high-risk PCa treated with RT vs. RP,
many investigators have sought to pool the above study types to
perform meta-analyses comparing outcomes of RT or RP with
respect to OM and PCM. Although BCR is commonly used as a
metric of clinical relapse in retrospective or observational studies
of PCa, there have been arguments against whether this is a
clinically meaningful endpoint. For instance, the definition of
biochemical recurrence differs depending on whether patients
receive upfront surgery or radiation, with the AUA definition
used in the former instance and the ASTRO or Phoenix criteria
most often used in the latter (58–60). Additionally, surgical
data suggest that at 5 years following BCR, ∼10% of men
will have developed clinical progression, and ∼5% will have
experienced PCM, with no association on multivariate analysis
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TABLE 2 | Selected population-based database studies comparing survival endpoints for prostatectomy vs. radiotherapy.
References Database
used/accrual period
Cohort described Key results Missing variables of study/
limitations of database used
Hoffman et al. (49) PCOS/SEER
(1994–2010)
1,655, including 437 high-risk
(PSA > 10 or Gleason ≥ 8)
treated with RP or XRT
High-risk results: RP was
associated with statistically
significant advantages for OM:
HR 0.65 (95% CI 0.48–0.87),
and PCM: HR: 0.36 (95% CI
0.20–0.64)
ADT duration
RT dose
RT modality/plan details
Small sample size
Sooriakumaran
et al. (50)
PcBaSe Sweden
(1996–2010)
32,846 including 7649 modified
NCCN high-risk
HR for PCM favors RP over RT:
HR = 1.50 (95% CI 1.19–1.88)
ADT use/duration
RT dose
RT modality/plan details
Ennis et al. (52) NCDB (2004–2013) Clinically localized, NCCN
high-risk who received RP or
XRT + ADT or XRT + BT ± ADT
No difference in OM between RP
and XRT + BT, XRT/ADT
associated with higher mortality
than RP (HR, 1.53; 95% CI,
1.22–1.92).
ADT use/duration
RT dose
RT modality/plan details
PCM
Jang et al. (56) SEER-Medicare
(1992–2009)
T3-T4N0M0 or T3-T4N1M0, age
≥65 treated with RP/adjuvant
XRT or XRT/ADT
10-year PCM and OM favored
men who underwent RP + XRT
over men who underwent XRT +
ADT
RT dose;
RT modality/plan details;
lack of specific information
regarding biochemical/clinical
recurrence; lack of
patient-reported outcomes; data
for non-Medicare beneficiaries
<65 years
Muralidhar et al.
(54)
NCDB and SEER
(2004–2012 for NCDB
and SEER)
cT1-T3N0M0, Gleason 9–10,
PSA 0–40 ng/ml treated with
XRT + BT or RP + ART
NCDB: No difference in 5-year
OM between RP + ART vs. XRT
+ BT (HR 1.10, 95% CI
0.95–1.27)
SEER: No difference in 5-year
PCM (HR 1.22, 95%
CI 0.88–1.71)
Limitations as above for SEER
and NCDB studies
ADT, androgen deprivation therapy; ART, adjuvant radiation therapy; BT, brachytherapy; HR, hazard ratio; OM, overall mortality; NCCN, National Comprehensive Cancer Network;
NCDB, National Cancer Database; PCM, prostate cancer-specific mortality; PSA, prostate-specific antigen; SEER, Surveillance, Epidemiology, and End Results; XRT, external beam
radiation therapy.
between time to BCR and risk of systemic progression or PCM
(40). The vast majority of meta-analyses have thus focused on
OM and PCM, two measures which are difficult for individual
observational studies to reliably assess because of an often large
sample size and follow-up required (27–30, 32, 61, 62). The
most well-known of these meta-analyses utilized pooled results
from >90,000 patients for OM and PCM estimates of HRs of
RT-based outcomes relative to RP in the setting of all clinically
localized PCa (Table 3). The study reported that patients treated
with RT had a statistically significant higher risk of death
(OM, HR, 1.63; 95% CI, 1.54–1.73; PCM, HR, 2.08; 95% CI,
1.76–2.47) (30). These findings were robust to subgroup and
sensitivity analysis, as well as covariates tested, including PCa risk
group, RT modality, follow-up duration, study accrual period,
or geographic region of the study. The authors even detected
a survival benefit in favor of RP even in the setting of low-
risk disease, an association that was not detected in the UK
ProtecT study that was published the same year (3). The authors
of this meta-analysis later commented that this result for low-
risk patients in the meta-analysis was potentially caused by a
statistical anomaly referred to as the Will Rogers phenomenon
and, perhaps more importantly, the strong possibility of residual
confounding (29, 38, 63, 64).
The findings of this meta-analysis, which has been widely
cited as the definitive pooling of observational studies to date
examining RP and XRT, have been scrutinized and criticized by
some (65–67). Roach et al. (29) attempted to elucidate possible
explanations for the magnitude of the HR in favor of surgery.
While most studies reporting HRs comparing relative efficacy
constructed from observational data utilized validated measures
of bias such as the Newcastle-Ottawa Scale or GRADE (68,
69), there is often limited reporting of ADT use, RT modality
and dose, or the use of adjuvant radiation in the setting of
adverse surgical features. Roach et al. constructed a “reliability
score” that incorporated a point-based system favoring studies
providing full details of staging with Gleason score, T stage, and
PSA. Studies were rewarded for demonstrating high compliance
with recommended ADT duration for high-risk disease, whereas
studies with limited reporting regarding ADT were penalized.
Perhapsmore controversially, extensive population-based studies
across multiple institutions and those utilizing >12,000 patients
were penalized, given a perceived inability to control for residual
confounding. Using this somewhat controversial technique,
which has been criticized by the authors of the previous meta-
analysis (38), Roach et al. demonstrated that the magnitude
of the HR estimator in favor of RP decreased for both OM
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TABLE 3 | Selected meta-analyses comparing prostate cancer-specific mortality
and overall mortality between radical prostatectomy and radiation therapy.
References Study
description
Results Notable
limitations
Wallis et al.
(30)
Meta-analysis of
19 studies of low
to moderate risk of
bias (Newcastle-
Ottawa used for
assessment), up
to 118,830 pooled
patients
Worse OM (aHR =
1.63) and PCM
(aHR=2.08) with
RT compared with
RP
Residual
confounding,
limited quality
control regarding
adequacy of ADT,
RT dose in
included studies
Roach et al.
(29)
Meta-analysis of
14 studies.
Stratified studies
by use of
“reliability score”
incorporating
comorbidity
adjustment, ADT
quality, and study
size
10-year OM and
PCM favored RP
over RT, by 10 and
4%, respectively.
Higher “reliability”
associated with
differences of 5.5
and 1%,
respectively.
Residual
confounding, use
of unvalidated
“reliability score”
based on
somewhat
subjective criteria
to stratify included
studies
ADT, androgen deprivation therapy; OM, overall mortality; PCM, prostate cancer-specific
mortality; RP, radical prostatectomy; RT, radiation therapy.
and PCM as the deemed “reliability” of the study increased
according to this metric. Although the criticism regarding the
use of an unvalidated “reliability score” must be acknowledged,
the study did highlight an apparent association between the
estimated degree of “surgical superiority” with larger studies that
incorporated limited reporting of ADT and RT compliance in the
setting of high-risk disease.
The vast majority of population-based studies and meta-
analyses pooling these data along with single-institution studies
point to superior OM and PCM outcomes with RP over RT.
Underlying these studies, however, is valid criticism surrounding
the degree to which large-scale studies can account for optimized
RT/ADT regimens.
CURRENT QUESTIONS OF INTEREST
RELATED TO OBSERVATIONAL DATA
REGARDING RP VS. RT
Interpreting Historical Results in Light of
Practice-Changing Clinical Trials
Multiple practice-changing clinical trials have been reported
in the past two decades that have led to changes in the
NCCN recommended standard of care for high-risk PCa, should
an upfront RT approach be chosen. Although the studies
included heterogeneous inclusion criteria and ADT durations
ranging from 4 months to lifelong treatment, multiple studies
were published that provided evidence of improved disease-
free survival and PCM (7–10). EORTC 22991 additionally
provided evidence that disease-free survival remains improved
in the setting of intermediate- to high-risk PCa with 6 months
of GnRH agonist ADT at 5 years in the context of dose-
escalated RT (11). There is continuing uncertainty regarding
the optimal duration of ADT in the setting of high-risk
disease, though multiple clinical trials have narrowed the typical
range recommended by NCCN to 1.5 years or longer when
ADT is used in combination with definitive XRT (12–15,
70, 71). Surveys have suggested that since the publication of
trials supporting prolonged ADT in the setting of high-risk
disease, compliance with longer ADT duration has increased.
Notably, however, there are distinct proportions of patients
up to ∼50% who continue to receive short-course ADT.
Concern regarding comorbidities and uncertainty in the era
of dose-escalation are occasionally cited as associated with
incomplete compliance (72–75). As such, investigators drawing
conclusions from large observational database studies must
remain cognizant that there are many reasons why current
treatment patterns for high-risk disease remain heterogeneous
and not necessarily consistent with level I data provided by
these RCTs. Investigators who wish to make such comparisons
need to take into account the ADT quality as a potential
confounder, along with traditional covariates examined in
modern database studies.
Current Questions Related to BT Boost
As discussed in the Introduction, the trend of RT in
clinically localized PCa, including high-risk disease, has been
to explore safe dose-escalation (76–80). With increasing
attention paid to both LDR and high-dose-rate (HDR) BT
boost utilized in combination with XRT, observational studies
providing comparison of treatment outcomes regarding RP vs.
combination XRT + BT ± ADT have been recently published
(42, 52–55, 81–83). This treatment regimen has sometimes been
referred to as ComboRT (54) or MaxRT (42). There has
been increased interest in studying treatment outcomes of this
regimen since the publication of the ASCENDE-RT trial that
demonstrated improved BF with the addition of I-125 LDR boost
to a minimum peripheral dose of 115Gy. This improved BF came
at the cost of a higher risk of genitourinary (GU) toxicity. The
ASCENDE-RT study notably included 69% of patients with high-
risk disease (6) and reaffirmed earlier retrospective evidence from
the Prostate Cancer Results Study Group (84).
There are no randomized data comparing XRT+BT regimens
to RP. Many have sought to address this retrospectively with
institutional series or multi-institutional registries (42, 81–
83). Perhaps most notable among the efforts among limited
institutions is a study cohort comprising 639 patients with
Gleason 9–10 PCa treated either with RP with pelvic lymph
node dissection in the Martini-Klinik Prostate Cancer Center in
Germany (n = 559) or Max-RT at the Chicago Prostate Cancer
Center (n = 80) (42). MaxRT was defined as a combination of
XRT, BT, and ADT. A strength of this study was the stratification
of surgical outcomes by receipt of adjuvant RT and ADT. Fifty
patients received MaxRP, defined as RP followed by adjuvant
XRT and ADT. The results pointed to significantly reduced
PCM for Gleason 9–10 PCa with MaxRT compared to RP,
with MaxRT patients receiving a median ADT duration of 6
months. Patients receivingMaxRP, however, did not demonstrate
a statistically significant difference in HR for PCM or OM, with
the authors computing a plausibility index for equivalence of
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treatment of 76.75% between the treatment arms of MaxRP and
MaxRT for PCM and 77.97% for OM. One limitation is a source
of bias introduced by the geographic separation between the
comparator groups.
This paper, along with the Kishan study described below,
has drawn the attention of others seeking to utilize large cancer
databases and registries to examine the same question. Relatively
few studies have been able to draw comparisons in OM (52–
55) and even fewer in PCM (54, 55). One study using SEER-
Medicare curiously reported a more favorable OM with XRT +
BT compared with RP but not PCM (55). Another study utilizing
the NCDB in a cohort with NCCN high-risk disease≤ 65 years of
age and with Charlson Comorbidity Index of 0 reported a worse
OM with XRT + BT compared with RP (53), a result that was
not seen in a larger cohort without age restriction (52). A recent
study utilizing both NCDB for comparisons of OM and SEER for
comparisons of PCM reaffirmed the apparent lack of statistically
significant difference in OM or PCM when comparing MaxRT
and MaxRP in patients with Gleason 9–10 disease, not observing
any evidence of favorable surgical outcomes in younger patients
<65 years (54). Although there is some heterogeneity among
the population-based studies when different populations of high-
risk disease and age are assembled, the majority of studies seem
to suggest a trend toward improved PCM when XRT + BT
boost is incorporated alongside ADT. Although associations
of improved PCM relative to RP have been contested, there
is less evidence suggesting superior surgical outcomes when
BT boost is incorporated alongside XRT/ADT. These studies
suggest that dose-escalation in the form of BT boost may form a
crucial role in achieving superior local control when upfront RT
is used.
Multi-Institutional Registries
Many groups have sought to achieve quality control for data
collection and reporting with customized multi-institutional
registry studies (Table 4). Assembling large numbers of patients
in a database between institutions does not by itself provide
a basis for reducing the potential for residual confounding;
the onus remains on participating investigators to thoughtfully
survey and record classifiers that ensure quality control and
facilitate necessary statistical adjustments. These registries allow
improved reporting of ADT regimens and compliance with
dose-escalated RT in the setting of high-risk PCa treatment
while maintaining the numbers necessary to provide statistical
power. Barnes-Jewish Hospital and Cleveland Clinic conducted
an early such effort. They published results of 10,429 patients
with clinically localized PCa treated with upfront RP, XRT, or
BT regimens, including 1,234 patients with D’Amico high-risk
disease (85). The authors found XRT associated with increased
OM and PCM compared to RP, with BT associated with increased
OM but not PCM. Propensity-matched adjusted HRs were
reported. This study had the advantage of 82% of high-risk
patients receiving XRT or BT receiving ADT. The study is limited
by the low radiation dose used and ADT duration delivered
for many patients, which are considered insufficient by current
standards. A subsequent study conducted by Duke University,
Chicago, and twenty-first Century Oncology focused solely on
patients <75 years of age with clinically localized Gleason 8–10
disease, treated with either XRT + BT with ADT or RP (81).
Patients received ADT for a median of 4.3 months, which started
before BT. Their study found that RP was not associated with
an increased risk of PCM compared with XRT + BT with ADT,
reporting an HR of 1.8 (95% CI, 0.6–5.6).
TABLE 4 | Multi-institutional registry studies.
Author, Institutions Inclusion criteria Comparison Findings
Kibel: Barnes-Jewish Hospital and
Cleveland Clinic (1995–2005) (85)
Clinically localized disease; general
cohort of 10,429 including 1,234
D’Amico high-risk patients
XRT/ADT or BT vs. RP
Note: XRT/ADT—median 74Gy
(Barnes-Jewish) or 78Gy (Cleveland
Clinic) and 82% of high-risk patients
received ADT (median 6 months)
Worse OM with XRT/ADT (HR, 1.7;
95% CI, 1.3–2.3) or BT (HR, 3.1; 95%
CI, 1.7–5.9) compared with RP,
though no detectable difference in
PCM in high-risk subset
Adjusted 10-year PCM of 1.8% (RP),
2.9% (XRT), or 2.3% (BT)
Westover: 21st Century Oncology,
Chicago Prostate Center, Duke
University (1988–2008) (81)
Clinically localized, Gleason 8–10,
age < 75
657 patients included
XRT + BT vs. RP
Note: XRT + BT included 45Gy +
minimum 90–108Gy BT
No detectable difference in PCM, i.e.,
PCM for RP not detected as worse
than CMT (HR, 1.8; 95% CI, 0.6–5.6)
Kishan: 12 tertiary centers (11 in the
United States, 1 in Norway) from
2000 to 2013 (83)
Gleason 9–10, clinically localized
disease
XRT + BT (MaxRT) vs. RP
Note: XRT- median 74.3Gy, XRT+BT
median 91.5 Gy, pelvic nodes
included in 40.7% of XRT patients
Improved OM and PCM with MaxRT
compared with RP
Adjusted 5-year PCM RP 12% (95%
CI, 8–17%); EBRT 13% (95% CI,
8–19%); and EBRT + BT, 3% (95%
CI, 1–5%)
PCM HR MaxRT vs. RP−0.38 (95%
CI, 0.21–0.68)
OM HR MaxRT vs. RP−0.66 (95%
CI, 0.46–0.96)
ADT, androgen deprivation therapy; BT, brachytherapy; CMT, combined modality therapy; Gy, gray; MaxRT, combination external beam radiation therapy and brachytherapy ± ADT;
OM, overall mortality; PCM, prostate cancer-specific mortality; RP, radical prostatectomy; RT, radiation therapy; XRT, external beam RT.
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TABLE 5 | Selected clinical trials studying various therapies including systemic, surgical, and radiation interventions in high-risk prostate cancer.
NCT ID # Phase Title Accrual and arms Treatment arms
Systemic therapy interventions
NCT03477864 1 Stereotactic body radiation therapy with
REGN2810 and/or ipilimumab before surgery in
treating participants with progressive advanced
or oligometastatic prostate cancer
Active
target enrollment: 24
three arms
Anti-PD1 monoclonal antibody (REGN2810) vs.
intraprostatic ipilimumab vs. a combination of
both, followed by SBRT + RP
NCT02023463 1 Enzalutamide, radiation therapy, and hormone
therapy in treating patients with intermediate or
high-risk prostate cancer
No longer recruiting
actual enrollment: 25
one arm
Enzalutamide + LHRH agonist with goserelin or
leuprolide, followed by RT and additional LHRH
agonist
NCT03177460 1 Daratumumab or FMS inhibitor JNJ-40346527
before surgery in treating patients with
high-risk, resectable localized or locally
advanced prostate cancer
Active
target enrollment:
30 two arms
Daratumumab (CD38 antagonist) vs. FMS
inhibitor JNJ-40346527(CSF-1R tyrosine
kinase inhibitor) followed by RP
NCT00099086 1 Docetaxel, radiation therapy, and hormone
therapy in treating patients with locally
advanced prostate cancer
No longer recruiting
actual enrollment: 20
one arm
RT + bicalutamide and GnRH analog prior to,
during, and after RT + concurrent docetaxel
NCT03821246 2 Neoadjuvant atezolizumab with or without
enzalutamide in localized prostate cancer given
before radical prostatectomy
Active
target enrollment: 68
three arms
Atezolizumab alone vs. in combination with
enzalutamide or in combination with
emactuzumab, followed by RP
NCT02506114 2 Neoadjuvant PROSTVAC-VF with or without
ipilimumab for prostate cancer
Active
target enrollment: 75
two arms
PROSTVAC-VF (PSA-based immunization) ±
ipilimumab, followed by RP
NCT02508636 2 Trial of radiotherapy with leuprolide and
enzalutamide in high-risk prostate
No longer
recruiting actual enrollment: 11
one arm
Definitive RT + Leuprolide + Enzalutamide
NCT02772588 2 AASUR in high-risk prostate cancer Active
target enrollment: 58
one arm
Leuprolide + Abiraterone + apalutamide +
SBRT
NCT02903368 2 Neoadjuvant and adjuvant abiraterone acetate
+ apalutamide prostate cancer undergoing
prostatectomy
No longer recruiting
actual enrollment: 120
two arms, crossover
Abiraterone, leuprolide, prednisone ±
apalutamide, followed by RP. Adjuvant
abiraterone, apalutamide, leuprolide,
prednisone vs. no adjuvant therapy.
NCT03436654 2 Multi-arm multi-modality therapy for very
high-risk localized and low volume metastatic
prostatic adenocarcinoma
Active
target enrollment: 76
two arms
Apalutamide ± (Abiraterone and prednisone)
followed by RP, pelvic lymphadenectomy,
GnRH agonist/antagonist
NCT03432780 2 Radiation-hormone and docetaxel vs.
radiation-hormone in patients with high-risk
localized prostate cancer (QRT-SOGUG)
No longer recruiting
actual enrollment: 134
two arms
RT + hormone therapy ± weekly docetaxel
NCT01385059 2 Axitinib before surgery in treating patients with
high-risk prostate cancer
No longer
recruiting actual enrollment: 60
two arms
Axitinib for 28 days vs. no therapy followed by
RP and pelvic lymph node dissection
NCT02849990 2 A phase II neoadjuvant study of apalutamide,
abiraterone acetate, prednisone, degarelix and
indomethacin in men with localized prostate
cancer pre-prostatectomy
No longer
recruiting actual enrollment: 22
one arm
Apalutamide, abiraterone, prednisone,
degarelix, indomethacin followed by RP
NCT03899987 2 Aspirin and rintatolimod with or without
interferon-alpha 2b in treating patients with
prostate cancer before surgery
Active
target enrollment: 60
two arms
Aspirin + rintatolimod ± recombinant interferon
alpha-2b followed by RP vs. RP alone
NCT02949284 2 Androgen receptor antagonist ARN-509 with or
without abiraterone acetate,
gonadotropin-releasing hormone analog, and
prednisone in treating patients with high-risk
prostate cancer undergoing surgery
Active
target enrollment: 90
two arms
Apalutamide ± (abiraterone acetate, GnRH
agonist, prednisone) followed by RP vs. RP
alone
NCT01409200 2 Antiandrogen therapy with or without axitinib
before surgery in treating patients with
previously untreated prostate cancer with
known or suspected lymph node metastasis
No longer
recruiting actual enrollment: 73
two arms
ADT + axitinib followed by RP and pelvic lymph
node dissection vs. ADT alone followed by RP
and pelvic lymph node dissection
NCT01546987 3 Hormone therapy, radiation therapy, and
steroid 17alpha-monooxygenase TAK-700 in
treating patients with high-risk prostate cancer
No longer
recruiting actual enrollment: 239
two arms
ADT + GnRH agonist + RT ± TAK-700 (steroid
17alpha-monooxygenase)
(Continued)
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TABLE 5 | Continued
NCT ID # Phase Title Accrual and arms Treatment arms
NCT03767244 3 A study of apalutamide in participants with
high-risk, localized or locally advanced prostate
cancer who are candidates for radical
prostatectomy (PROTEUS)
Active
target enrollment: 1,500
two arms
ADT + apalutamide OR placebo, followed by
RP, followed by adjuvant ADT + apalutamide
OR placebo
NCT00288080 3 Hormone therapy and radiation therapy or
hormone therapy and radiation therapy
followed by docetaxel and prednisone in
treating patients with localized prostate cancer
No longer
recruiting actual enrollment: 612
two arms
Androgen suppression with LHRH agonist +
oral anti-androgen prior to and concurrent with
RT, followed by adjuvant LHRH agonist ±
docetaxel x six cycles
NCT00430183 3 Surgery with or without docetaxel and
leuprolide or goserelin in treating patients with
high-risk localized prostate cancer
No longer
recruiting actual enrollment: 788
two arms
Docetaxel + LHRH agonist + surgery vs.
surgery alone
Surgical interventions
NCT00007644 3 Prostate cancer intervention vs. observation
trial (PIVOT)
Results published; pending
long-term results actual
enrollment: 731 two arms
RP vs. observation
N/A 3 Radical prostatectomy or watchful waiting in
early prostate cancer (SPCG-4)
Results published; pending
long-term results actual
enrollment: 695 two arms
Watchful waiting vs. RP
NCT02102477 3 Surgery vs. radiotherapy for locally advanced
prostate cancer (SPCG-15)
Active
target enrollment: 1,200
two arms
RP ± adjuvant or salvage RT, vs. RT with
adjuvant ADT
Radiation therapy interventions
NCT02830165 1 Stereotactic body radiation therapy in treating
patients with high-risk prostate cancer
undergoing surgery
Active
target enrollment: 12
one arm
SBRT given over three fractions ∼2–4 weeks
prior to RP
NCT02346253 1 | 2 High-dose brachytherapy in treating patients
with prostate cancer
Active
target enrollment: 163
one arm
High-dose brachytherapy over two fractions +
ADT
NCT00951535 2 A prospective phase II dose-escalation study
using IMRT for high-risk N0 M0 prostate
cancer. ICORG 08-17
No longer
recruiting actual enrollment: 251
Dose-escalation study from baseline of 75.6Gy
up to a maximum of 81Gy, depending on
volume constraints
NCT01368588 3 Androgen-deprivation therapy and radiation
therapy in treating patients with prostate
cancer (RTOG 0924)
No longer recruiting
actual enrollment: 2,592
two arms
RT to prostate and seminal vesicles alone vs.
whole-pelvis RT
NCT00967863 3 Radiation therapy in treating patients receiving
hormone therapy for prostate cancer
(GETUG-AFU 18)
No longer
recruiting actual enrollment: 500
two arms
RT to 80Gy vs. to 70Gy given in conjunction
with ADT
NCT00667888 3 A phase III intensity radiotherapy
dose-escalation for prostate cancer using
hypofractionation
No longer
recruiting actual enrollment: 225
two arms
RT to 75.6Gy in 42 fractions vs. RT to 72Gy in
30 fractions
Other interventions
NCT03514927 2 High-intensity focused ultrasound in treating
participants with intermediate and high-risk
prostate cancer
Active
target enrollment: 32
one arm
High-intensity focused ultrasound (HIFU)
followed by RP
ADT, androgen deprivation therapy; Gy, gray; IMRT, intensity-modulated radiation therapy; LHRH, Luteinizing hormone-releasing hormone; PSA, prostate-specific antigen; RP, radical
prostatectomy; RT, radiation therapy; SBRT, stereotactic body radiotherapy.
The most impressive multi-institutional registry endeavor to
date was conducted by the University of California, Los Angeles,
the California Endocurie Therapy Center, and Fox Chase,
broadening to include 12 tertiary centers. These two studies
focused on Gleason 9–10 PCa, comparing PCM, OM, and distant
metastasis for patients receiving RP, XRT with ADT, or XRT +
BT combined with ADT (82, 83). The more extensive publication
included 1,809 patients. The authors reported high-quality ADT,
including XRT and XRT+ BT arms that received 89.5 and 92.4%
utilization of ADT as part of the initial treatment strategy, with
median durations of 21.9 and 12 months, respectively. After the
inverse probability of treatment weighting adjustments, XRT +
BT was associated with a significantly longer time until distant
metastases (DM) and lower PCM than either XRT or RP. One
potential limitation to interpreting the outcomes from the RP
arm includes the relatively low utilization of adjuvant RT of
8.7% for Gleason 9–10 disease, with salvage performed in 34.1%
of patients. On examination of subgroups by radiation dose,
patients receiving <70Gy had a significantly higher rate of PCM
than either those receiving ≥78Gy, though this relationship did
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not hold with DM. The registry did not record and control for
comorbidity status, which is a limitation regarding adjustment of
HRs between RT and RP. The authors speculated that the lack of
this information was unlikely to bias their conclusion in favor of
RT, as RT cohorts typically have more comorbidities.
These efforts, conducted by urologists and radiation
oncologists alike, have contributed unique opportunities to
assemble large cohorts of patients across institutions with a
level of quality control regarding recommended treatment
compliance, perhaps second only to prospectively organized
studies or RCTs. It is likely that these efforts will continue to
answer questions too detailed for standard cancer registries, yet
impossible to address with currently available RCT data.
Addition of Systemic Therapies; Limited
Data Available From Randomized Trials
There has been much interest in both past and current
clinical trials to explore the addition of chemotherapy to long-
term ADT and dose-escalated RT, with currently available
prospective randomized trials demonstrating limited follow-
up (23–26). Available data from GETUG 12, RTOG 0521,
and the non-metastatic subgroup of STAMPEDE point to
an improved relapse-free survival associated with the use of
docetaxel in patients treated with XRT + ADT (24, 25, 86),
with recently updated data from RTOG 0521 demonstrating an
additional improvement in DM (24). Data are still maturing
from the majority of available clinical trials, and the decision
to use chemotherapy is currently individualized based on
patient disease characteristics. There are limited data, especially
regarding the interplay between MaxRT incorporating BT and
systemic therapy strategies. More extensive recent systematic
review and discussion of currently available prospective trials,
additionally including consideration of second-generation ADT
and adjuvant treatments following surgery, are provided
elsewhere (26).
CURRENT PROSPECTIVE TRIALS OF
INTEREST
There are multiple active clinical trials currently underway
investigating various promising therapeutic interventions for
high-risk PCa. The majority of these clinical trials are early-
phase (phase I or II). The principal role of these studies is to
investigate the role of additional systemic treatment modalities
or evaluate the most effective timing of systemic therapy
in relation to definitive local treatment modalities such as
surgery or radiation. Furthermore, with the surge in interest in
immunotherapies for cancer as a whole, high-risk PCa has been
seen as a potential area for the integration of further immune
treatments into the current standard of care. For example, trial
NCT03477864 investigates the safety of injecting intravenous
anti-PD1 monoclonal antibody and intraprostatic ipilimumab
(either alone or in combination with each other) in the setting of
high-risk PCa, to be followed by both SBRT and RP as definitive
local modalities. In addition, a phase II trial (NCT02506114) is
evaluating the efficacy of a PSA-based form of immunization,
with or without additional immunotherapy with ipilimumab,
prior to definitive local treatment with RP for high-risk PCa.
This is not to say that traditional chemotherapeutic regimens
have been overlooked, however; the QRT-SOGUG phase II trial
(NCT03432780), of which a preliminary report of results was
published in abstract format in 2016, is investigating the safety
and efficacy of administering weekly docetaxel concurrently with
standard dosing of RT and ADT (87). In addition, there is interest
in adapting hormone therapy regimens to incorporate the
newest generation of drugs such as apalutamide and abiraterone;
the phase II trial NCT02949284 is a trial that is examining
the feasibility of performing nerve-sparing RP in the setting
of apalutamide given either alone or in combination with
abiraterone and prednisone.
There have been relatively fewer phase III trials investigating
the role of surgical intervention in high-risk PCa. These include
the PIVOT trial, which most recently reported results in 2017
with a median of 12.7 years of follow-up; the PIVOT trial
randomly assigned 731 individuals with a diagnosis of localized
PCa to observation or RP, and found that the RP arm did not have
significantly lower OMor PCM compared to the observation arm
(88). Notably, there was a trend toward significance for these
metrics in the higher-risk populations–namely, those with a PSA
value of >10 and a Gleason score of 7 or higher. In contrast,
the SPCG-4 trial, which randomized 695 men with localized PCa
to watchful waiting or RP, did demonstrate a benefit to surgery,
with a number needed to treat to prevent one death of eight (89).
Nevertheless, in the high-risk group of patients in this trial, there
was no significant difference in OM, PCM, and risk of metastases,
as of the most recent results in 2014 with over 23 years of follow-
up. The next generation of trials is found in the phase III SPCG-
15 trial, which is currently active and recruiting with a target
enrollment of 1,200 patients (45). This trial enrolls patients with
locally advanced PCa and randomizes them to either standard of
care with radiation and ADT vs. RP (including extended pelvic
lymph node dissection) with adjuvant or salvage radiation and
hormone therapy if necessary; the primary endpoint is cause-
specific survival.
Also, multiple trials are actively investigating variations upon
the currently accepted dose, fractionation scheme, and method
of delivery of RT for locally advanced high-risk PCa. Phase
I trials such as NCT02830165 investigate the safety of adding
of hypofractionated stereotactic RT given prior to RP, with
the hypothesis that providing patients with two forms of local
therapy may aid in increased disease control as well as prompt
an immune response in high-risk disease (90). The phase I/II
trial NCT02346253, which is not limited to high-risk patients
but includes patients up to T3 and a Gleason score of 10,
seeks to answer whether HDR-BT delivered over two fractions,
in conjunction with ADT and luteinizing hormone-releasing
hormone (LHRH) agonist therapy, is safe and efficacious (as
assessed by the rates of genitourinary toxicity, PSA nadir, and
rates of freedom from biochemical failure). How radiation fields
should be defined–that is, in terms of whole-pelvis RT vs.
RT to the prostate and seminal vesicles alone–is under active
investigation as well in the trial NCT01368588 (RTOG 0924).
With an accrual of over 2,500 patients, it is powered to answer
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the question of overall survival differential between these two
radiation field setups in patients with a moderate or high risk of
recurrence. Dose-escalation continues to be actively investigated
as well. For example, NCT00967863 (GETUG-AFU 18) examines
the impact of dose-escalation to 80Gy (vs. a standard of 70Gy)
in high-risk PCa patients in a phase III randomized setting;
as of November 2015, there was no increased toxicity noted
acutely or at 1-year follow-up, but the results for biochemical
and clinical control are still pending at this time (91). Other
local treatment options have continued to remain of interest.
The phase II single-arm trial NCT03514927 seeks to determine
whether high-intensity focused ultrasound (HIFU) can be used in
conjunction with RP to impact the percent of viable cancer tissue
noted on the surgical pathology specimen. Overall, the general
thrust of the new emerging data and clinical trials appears to be in
adding various systemic therapies, particularly in new hormonal
treatments and incorporation of immunotherapies, with some
studies also looking at the role of surgery and modifying current
radiation techniques and dosages.
CONCLUSIONS
So far, RCTs assessing OM and PCM between RP and RT
are limited concerning representation of high-risk, clinically
localized disease. Most observational studies and meta-analyses
have not historically supported oncologic equivalence between
the two modalities. Issues of selection bias, inadequate use
of ADT/radiation dose, and residual confounding remain as
difficulties in interpreting available retrospective data. Trends
have demonstrated more recent curation of multi-institutional
registries and databases. These have allowed assessment of
outcomes for patients receiving treatment showing improved
compliance with modern evidence-based RT/ADT and
RP/adjuvant RT regimens. High-dose RT incorporating BT
boost has demonstrated evidence of improved PCM. With more
recent efforts, estimates of differences in PCM between RT- and
RP-based approaches have diminished. There is still a relative
lack of prospective randomized trials being organized to provide
a comparison between RP and RT strategies, with the majority
of trials exploring new hormonal therapies, immunotherapies,
and in general augmentation of existing strategies. Likely,
retrospective data will still be a significant resource in answering
questions regarding the interplay of RP- and RT-based modalities
for high-risk PCa.
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